

C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson's Consortium



<u>AcureX</u> is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an initial focus on Parkinson's disease. To achieve this, AcureX leverages a first-in-class peripheral drug-responsive biomarker assays to molecularly define and segment patients in combination with novel disease-modifying therapeutics. AcureX is ushering in a new era of precision medicine to treat the right patients with the right drug at the right time – and is doing so with a focus on industry and nonprofit collaboration to drive success.

We are thrilled for AcureX to support CPP's mission and objectives by sharing their knowledge and expertise.